Emerging antibody combinations in oncology

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are a key therapeutic strategy for human diseases, particularly in oncology.
• Current anti-cancer antibody therapies target growth factors, angiogenesis, induce apoptosis, or block immune checkpoints.
• Tumor complexity and pathway redundancy often lead to treatment resistance, limiting curative potential.

Purpose of the Study:

• To review emerging antibody therapeutic combinations for cancer treatment.
• To explore strategies for improving the efficacy and durability of antibody-based therapies.
• To discuss combinations targeting single or multiple biological pathways.

Main Methods:

• Literature review of antibody therapeutics in oncology.
• Analysis of combination strategies for monoclonal antibodies.
• Discussion of therapeutic mechanisms including immunomodulation and angiogenesis inhibition.

Main Results:

• Few antibodies are curative due to tumor biological complexities and resistance mechanisms.
• Combinations of antibody therapeutics are emerging to enhance treatment effectiveness.
• Strategies involve combining antibodies within a single pathway or across multiple pathways.

Conclusions:

• Combining monoclonal antibodies offers a promising approach to overcome treatment resistance in cancer.
• Targeting multiple biological pathways simultaneously or sequentially can improve therapeutic outcomes.
• Further research into antibody combinations is crucial for advancing cancer treatment.